Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2
Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C. Wainwright Genetic Medicines Virtual Conference 2025: Fireside chat will be available to view on demand beginning Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.Chardan’s 9th ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Citi’s 2025 Biopharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025, at 4:45 p.m. ET in Boston, MA.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Monday, September 8, 2025, at 1:0...
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- -- Completed follow-on offering, raising $144.2 million in gross proceeds and extending cash runway into 2027 -- -- Secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to advance Prime Editors for Cystic Fibrosis -- -- Announced leadershi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.